医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cholesterol Beats Swine Flu, Avian Flu and Corona Viruses: Viroblock Launches New Face Mask

2013年06月26日 PM05:25
このエントリーをはてなブックマークに追加


 

GENEVA, Switzerland

Viroblock SA, a Swiss start-up, today presented new data at ICPIC 2013 in Geneva, showing that their face-mask containing proprietary novel cholesterol depletion technology traps and kills over 99.9995% of H1N1 flu viruses (swine flu), 99.999% of H5N1 flu viruses (avian flu) and 99.997% human corona viruses on pass through air. Aimed at helping protect people from these respiratory pathogens, the mask is up to one hundred times more effective than a similar mask without Viroblock technology. The company will now start direct sales in Switzerland and is looking for distributors in other countries.

“Aerobiology tests for face-masks simulate real life situations, in which the user is exposed to viruses coming in. The mask helps prevent transmission from and to the person wearing the mask.” commented Dr Thierry Pelet, CSO at Viroblock. “The stringent testing demonstrates the efficacy and speed at which the cholesterol depletion technology works”.

Aerobiology tests, carried out in high security laboratories, create a mist of viruses on the outside of the mask, a pump is used to draw air and viruses through the mask, and finally testing for live virus occurs on the inside of the mask.

“We believe that our protective face-mask can help protect healthcare, agriculture and security workers effectively, with added advantages of comfort of wear and easy identification,” said Dr Jamie Paterson, CEO of Viroblock.

Viroblock SA is a CTI Certified Swiss start-up located in Geneva, Switzerland. Founded in 2006 and supported mainly by Swiss investors, the company is focused on developing a unique anti-viral technology based on cholesterol depletion. Viroblock’s first product is an anti-viral face mask and other air filtration products are planned. For more information about Viroblock, please visit: www.viroblock.com. Viroblock is also available on Facebook and Twitter.

– ends –

CONTACT

Genevensis Healthcare Communications
Danièle Castle
T: 079 202
6667
Mail: info@genevensis.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc